

## **CORONAVIRUS COVID-19 EMERGENCY: FRIULCHEM IS CONTINUING WITH PRODUCTION ACTIVITIES**

Milan, 23 March 2020 - **Friulchem S.p.A.** (AIM: FCM), innovative SME and one of the main Italian operators at international level in R&D and in the production on behalf of third parties (CDMO) of semi-finished and finished products containing pharmaceutical active ingredients, dietary supplements, specialising in particular in drug delivery for the veterinary sector, following the issuing of the Decree of the President of the Council of 22 March 2020 with the new restriction on the country's production activities as an additional measure to contain and manage the **COVID-19** epidemiological emergency, **communicates that** by providing essential services to ensure the health of animals, necessary like those of humans for guaranteeing food quality, the **production activities** of the Vivaro facility **will continue as normal**. As of today, there are no problems in relation to the supply of raw materials, as well as the production and shipping of products all over the world. The company also states that, in line **with its growth plans**, it is continuing to carry out its strategic business.

**Friulchem thanks all its employees** and partners operating today at the Vivaro facility, stressing that, in order to protect their health and that of their families, all the necessary hygiene measures and precautions have been taken.

\*\*\*

**Friulchem (AIM:FCM)**, a company that has been operating in this sector for over 20 years, is today one of Italy's leading CDMOs (*Contract Development Manufacturing Organisations*) operating internationally in the healthcare sector. It offers third-party research, development and manufacturing services for semi-finished and finished products containing both active pharmaceutical ingredients and food supplements. It primarily specialises in drug delivery systems for the veterinary sector, providing Friulchem's trademark excellence, as well as in the development of dossiers for generic medicines for human use. Friulchem is an innovative SME and B2B company which prides itself on its end-customer focus, and has deep Italian roots, thanks to its manufacturing facilities in Vivaro (Pordenone) and administrative headquarters in Milan. The Company is strongly oriented towards R&D activities and boasts established relationships with leading multinational companies in the pharmaceutical sector.

Common Shares ISIN: IT0005378457 - Friulchem Warrant ISIN: 2019-2022 IT0005378366

**Friulchem S.p.A.**

[ir@friulchem.com](mailto:ir@friulchem.com)

Tel: +39 02 36591450

**Integrae SIM S.p.A. – Nominated Adviser**

Giulia Mucciariello

[info@integraesim.it](mailto:info@integraesim.it)

Tel: +39 02 87208720

**CDR Communication - Investor and Media Relations**

Silvia Di Rosa [silvia.dirosa@cdr-communication.it](mailto:silvia.dirosa@cdr-communication.it)

Marianna Tremolada [marianna.tremolada@cdr-communication.it](mailto:marianna.tremolada@cdr-communication.it)